{"id":"W4295828577","doi":"10.1016/j.annonc.2022.07.1303","title":"1180P Treatment patterns and progression-free survival in MET exon 14 (METex14) skipping advanced non-small cell lung cancer (aNSCLC) in real-world clinical practice","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"EMD Serono; Eisai; Merck KGaA; Sanofi; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Pembrolizumab; Crizotinib; Nivolumab; Internal medicine; Oncology; Lung cancer; Progression-free survival; Pemetrexed; Real world data; Chemotherapy; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002908449,0.0001049677,0.0002565873,0.0004214714,0.0003159829,0.0006022269,0.0002032829,0.0004843112,0.001611162],"category_scores_gemma":[0.001869725,0.0001387909,0.0002035774,0.0007967181,0.0002221775,0.0004126561,0.0002779708,0.0004112996,0.0002676872],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004218077,"about_ca_system_score_gemma":0.0003536297,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002575581,"about_ca_topic_score_gemma":0.004665922,"domain_scores_codex":[0.9996606,0.00007239751,0.00004512686,0.00008529268,0.00005606795,0.00008053798],"domain_scores_gemma":[0.9991919,0.0001636056,0.0003618921,0.0000241916,0.00007347573,0.0001849397],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0004182881,0.00006725593,0.9867116,0.00002686269,0.00004480172,0.0005044832,0.0001282884,0.0001059075,0.0006537317,0.00005029234,0.0004312502,0.01085718],"study_design_scores_gemma":[0.00003485705,0.0003239368,0.9948581,0.00003327012,0.00006007717,0.001968713,0.0006752068,0.0004850285,0.0001964446,0.0001538033,0.001201122,0.000009357164],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9984049,0.0004976644,0.0000478215,0.0002089168,0.000008198297,0.00000538685,0.0002034139,0.000002859036,0.000620748],"genre_scores_gemma":[0.999375,0.0001646009,0.00004842866,0.00006881788,0.000009246034,0.00000344583,0.000163156,0.000002195236,0.0001649747],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002575581,"threshold_uncertainty_score":0.005389929,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08671700921615552,"score_gpt":0.5028440010374505,"score_spread":0.416126991821295,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}